Trial reportDisease markers2014
Individually tailored screening of susceptibility to sarcopenia using p53 codon 72 polymorphism, phenotypes, and conventional risk factors.
Trial report in Disease markers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Trial
- Can psychobiotics intake modulate psychological profile and body composition of women affected by normal weight obese syndrome and obesity? A double blind randomized clinical trial.Journal of translational medicine · 2017Trial
- Normal Weight Obesity Overview and Update: A narrative review.Current obesity reports · 2025Review
- Lean nonalcoholic fatty liver disease and sarcopenia.Frontiers in endocrinology · 2023Review
- The Risk of Sarcopenia among Adults with Normal-Weight Obesity in a Nutritional Management Setting.Nutrients · 2022Article
- Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms and their haplotypes in susceptibility to sarcopenia in Iranian older adults.BMC geriatrics · 2022Article
- Normal weight obesity and unaddressed cardiometabolic health risk-a narrative review.International journal of obesity (2005) · 2021Review
- Fasting: How to Guide.Nutrients · 2021Article
- Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge.International journal of molecular sciences · 2021Review
- From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.International journal of obesity supplements · 2020Review
- Obesity subtypes, related biomarkers & heterogeneity.The Indian journal of medical research · 2020Review
- Prevention and Treatment of Sarcopenic Obesity in Women.Nutrients · 2019Review
- Why primary obesity is a disease?Journal of translational medicine · 2019Review
- Physical Activity and Nutrition INfluences In ageing (PANINI): consortium mission statement.Aging clinical and experimental research · 2018Article
- The influence of diet on anti-cancer immune responsiveness.Journal of translational medicine · 2018Review
- Replication study of the vitamin D receptor (VDR) genotype association with skeletal muscle traits and sarcopenia.Aging clinical and experimental research · 2016Article
- Association of body composition and eating behavior in the normal weight obese syndrome.Eating and weight disorders : EWD · 2016Article
- New obesity classification criteria as a tool for bariatric surgery indication.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimp53 activity plays a role in muscle homeostasis and skeletal muscle differentiation; all pathways that lead to sarcopenia are related to p53 activities. We investigate the allelic frequency of the TP53 codon 72 in exon 4 polymorphism in the Italian female population and the association with appendicular skeletal muscle mass index in normal weight (NW), normal weight obese (NWO), and preobese-obese (Preob-Ob) subjects.
methodsWe evaluated anthropometry, body composition, and p53 polymorphism in 140 women distinguished in NW, NWO, and Preob-Ob.
results*Arg/*Arg genotype increases sarcopenia risk up to 20% (*Arg/*Arg genotype OR = 1.20; 95% CI = 0.48-2.9; *proallele carriers OR = 0.83; 95% CI = 0.83-2.06). The risk of being sarcopenic for *Arg/*Arg genotype in NWO and Preob-Ob is 31% higher than NW carriers of *proallele (RR = 0,31, 95% CI = 0,15-0,66, P = 0,0079). We developed a model able to predict sarcopenia risk based on age, body fat, and p53 polymorphism.
conclusionOur study evidences that genotyping TP53 polymorphism could be a useful new genetic approach, in association with body composition evaluations, to assess sarcopenia risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.